Xagrid

Land: Den Europæiske Union

Sprog: engelsk

Kilde: EMA (European Medicines Agency)

Aktiv bestanddel:

Anagrelide

Tilgængelig fra:

Shire Pharmaceuticals Ireland Limited

ATC-kode:

L01XX35

INN (International Name):

anagrelide

Terapeutisk gruppe:

Antineoplastic agents,

Terapeutisk område:

Thrombocythemia, Essential

Terapeutiske indikationer:

Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET is defined by one or more of the following features: >60 years of age or;, a platelet count >1000 x 109/l or;, a history of thrombohaemorrhagic events.,

Produkt oversigt:

Revision: 33

Autorisation status:

Authorised

Autorisation dato:

2004-11-15